Susceptibility of Candida spp. clinical isolates to antimycotics and disinfectants

Central European Journal of Biology

Volumn 5, Issue 6, 2010, Pages 821-826

  Staniszewska, Monika ^a   Rozbicka, Beata ^a   Rajnisz, Aleksandra ^a   Bocian, Ewa ^b   Wasińska, Ewa ^b   Jakimiak, Bozenna ^a   Röhm Rodowald, Ewa ^a   Kurza̧tkowski, Wiesław ^a   Tyski, Stefan ^b,c  

^a NATIONAL INSTITUTE OF HYGIENE   (Poland)

^b NATIONAL MEDICINES INSTITUTE   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Antifungal drugs; Antiseptic; Candida spp.; Disinfectants; Yeast susceptibility

Indexed keywords

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; FUNGI;

EID: 77957239312     PISSN: 1895104X     EISSN: 16443632     Source Type: Journal    
DOI: 10.2478/s11535-010-0068-3     Document Type: Article

References (23)

1. Colombo A. L, Perfect J., DiNubile M., Bartizal K., Motyl M., Hicks P., et al., Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-bind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis, Eur. J. Clin. Microbiol. Infect. Dis., 2003, 22, 470-474.
2. Hobson R. P., The global epidemiology of invasive Candida infections - is the tide turning?, J. Hosp. Infect., 2003, 55, 159-168.
3. Schelenz S., Management of candidiasis in the intensive care unit, J. Antimicrob. Chemother., 2008, 61, i31-i34.
4. Elie Ch. M., Lott T. J., Reiss E., Morrison Ch. J., Rapid identification of Candida species with species-specific DNA probes, J. Clin. Microbiol., 1998, 36, 3260-3265.
5. Gualco L., Debbia E. A., Bandettini R., Pescetto L., Cavallero A., Ossi M. C., et al., Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults, Int. J. Infect. Dis., 2007, 29, 179-184.
6. Swinne D., Watelle M., van der Flaes M., Nolard N., In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study), Mycoses, 2004, 47, 177-183.
7. Safdar A., Chaturvedi V., Koll B. S., Larone D. H., Perlin D. S., Armstrong D., Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles to bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida susceptibility trends study, 1998 to 1999), Antimicrob. Agents Chemother., 2002, 46, 3268-3272.
8. Espinel-Ingroff A., Boyle K., Sheehan D. J., In vitro activities of voriconazole an reference agents as determined by NCCLS methods: review of the literature, Mycopathologia, 2001, 150, 101-115.
9. Pfaller M. A., Diekema D. J., Messer S. A., Boyken L., Hollis R. J., Jones R. N., The International Fungal Surveillance Participant Group, In vitro activities of voriconazole, posaconazole and four licensed systemic antifungal agents against Candida species infrequently isolated from blood, J. Clin. Microbiol., 2003, 41, 78-83.
10. Arendrup M. C., Fuursted K., Gahrn-Hansen B., Schönheyder H. C., Knudsen J. D., Jensen I. M., et al., Semi-national surveillance of fungemia in Denmark 2004-2006; increasing incidence of fungemia and numbers of isolates with reduced azole susceptibility, Clin. Microbiol. Infect., 2008, 14, 487-494.
11. Tortorano A. M., Kibbler C., Peman J., Bernhardt H., Klingspor L., Grillot R., Candidaemia in Europe: epidemiology and desistance, Int. J. Antimicrob. Agents., 2006, 27, 359-366.
12. Quindos G., Sanchez-Vargas L. O., Villar-Vidal M., Eraso E., Alkorta M., Hernandez-Almaraz J. L., Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre, Int. J. Antimicrob. Agents, 2008, 31, 266-271.
13. Falagas M. E., Ntziora F., Betsi G. I., Samonis G., Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials, Int. J. Antimicrob. Agents, 2007, 29, 136-143.
14. th Ed., Lippincott Willams & Wilkins, Philadelphia, 2001, 617-639.
15. Penna T. C., Mazzola P. G., Martins A. M, The efficacy of chemical agents in cleaning and disinfection programs, BMC Infect. Dis., 2001, 1, 16-23.
16. Staniszewska M., Jakimiak B., Rohm-Rodowald E., Bocian E., Kurza{ogonek}tkowski W., Tyski S., Antifungal agents: susceptibility of different fungal strains to various disinfecting agents, Mikol. Lek., 2009, 16, 210-214.
17. European Committee for Standardization; EN 1275: 2005: Chemical disinfectants and antiseptics-Quantitative suspension test for the evaluation of basic fungicidal or basic yeasticidal activity of chemical disinfectants and antiseptics - Test method and requirements (phase 1), Brussels, France.
18. rd Ed., M27-A3, vol. 28, Clinical and Laboratory Standards Institute, Pennsylvania, 2008.
19. Maxwell M. J., Messer S. A., Hollis R. J., Boyken L., Tendolkar S., Diekema D. J., et al., International Fungal Surveillance Participant Group, Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical Isolates of Candida Species infrequently isolated from blood, J. Clin. Microbiol., 2003, 41, 1087-1090.
20. Krogh-Madsen M., Arendrup M. C., Heslet L., Knudsen J. D., Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient, Clin. Infect. Dis., 2006, 42, 938-944.
21. Wakieć R., Prasad R., Morschhäuser J., Barchiesi F., Borowski E., Milewski S., Voriconazole and multidrug resistance in Candida albicans, Mycoses, 2007, 50, 109-115.
22. Terleckyj B., Axler D. A., Qantitative neutralization assay of fungicidal activity of disinfectants, Antimicrob. Agents Chemother., 1987, 31, 794-798.
23. McDonnell G., Russell A. D., Antiseptics and disinfectants: Activity, Action, and Resistance, Clin. Microbiol. Rev., 1999, 12, 147-179.